The global vutrisiran industry is experiencing unprecedented growth, with market valuation rising from USD 671.96 Million in 2023 to an anticipated USD 2,087 Million by 2033, registering a robust CAGR of 12% during the forecast period from 2023 to 2033. This impressive expansion underscores the pivotal role of vutrisiran in addressing unmet medical needs for hereditary transthyretin-mediated amyloidosis (hATTR).
The market’s upward trajectory reflects growing optimism surrounding vutrisiran as an innovative therapeutic option. hATTR, a rare genetic disorder characterized by the accumulation of misfolded transthyretin proteins, leads to progressive and debilitating symptoms affecting the nervous and cardiovascular systems. Vutrisiran offers a promising solution, enhancing the quality of life for affected individuals by targeting the underlying mechanisms of the disease.
During the historical period from 2018 to 2022, the vutrisiran industry exhibited steady growth, achieving a CAGR of 5.1%. However, advancements in drug development and increased awareness of hATTR have accelerated market expansion in recent years.
Key Drivers of Market Growth:
- Breakthrough Therapeutic Potential: Vutrisiran’s efficacy in reducing transthyretin protein accumulation has positioned it as a leading treatment choice for hATTR patients.
- Increasing Diagnosis Rates: Growing awareness and advancements in diagnostic technologies are driving earlier detection of hATTR, amplifying demand for effective treatments.
- Rising Investments in Rare Disease Therapies: Pharmaceutical companies and research institutions are increasingly investing in the development of therapies for rare genetic disorders, bolstering the market outlook for vutrisiran.
Market Outlook and Future Opportunities:
With the healthcare sector prioritizing the development of targeted therapies for rare and debilitating diseases, the vutrisiran industry is poised for sustained growth. Stakeholders, including pharmaceutical companies, healthcare providers, and patient advocacy groups, are expected to play a critical role in shaping the market landscape.
Increased Market Insight Demand: Get Thorough Analysis and Trends in Our Complete Report!
Key Takeaways from the Market Study:
- The global Vutrisiran market is expected to grow with a 12% CAGR during 2023 to 2033.
- Hospital pharmacies are expected to hold 46% of the market share in 2023 for Vutrisiran market.
- North America is expected to possess 45% market share for Vutrisiran industry in 2023.
- Europe vutrisiran industry size is expected to possess 41% market share in 2023.
“The safety and efficacy of Vutrisiran have been demonstrated in clinical trials. Owing to this, key players are investing in the development of vutrisiran,” states an FMI analyst
Competitive Landscape:
Key players in the vutrisiran industry are Alnylam Pharmaceuticals, Inc., Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer, Ultragenyx Pharmaceutical, Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Merck & Co., Inc., Teva Pharmaceuticals
- Alnylam Pharmaceuticals has a strong pipeline of other RNAi-based therapies in development for a range of diseases. The success of Vutrisiran has helped to drive investor confidence in the company and increase funding for its other pipeline drugs, which could result in new treatment options for patients.
- Alnylam Pharmaceuticals has established patient access programs to ensure that patients who need Vutrisiran have access to the drug. These programs provide financial assistance, support services, and other resources to help patients access and afford Vutrisiran.
Key Segments Profiled in the Vutrisiran Industry Survey:
Drug Class:
- Antisense Oligonucleotides
- Nucleic Acids
- Nucleotide
- Nucleosides
Route of Administration:
- Injectable
- Parenteral
- Subcutaneous
Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube